Navigation Links
Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
Date:6/30/2008

BEIJING, June 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced the initiation of volunteer enrollment in its Phase II clinical trial for its split pandemic influenza vaccine. The preliminary results from this study are expected to be available in early 2009.

The randomized and double-blind trial is expected to enroll 210 adolescents, between the ages of 12 to 17, who will receive doses of 10ug, 15ug or 30ug, and 140 children, between the ages of 3 to 11, who will receive doses of 10ug or 15ug. Volunteers will be followed for two months with safety and immunogenicity data collected for the assessment of the vaccine.

Mr. Weidong Yin, Chairman, President and CEO, commented, ''Split influenza vaccine is believed to cause less adverse reactions in children compared to whole-viron influenza vaccine. Sinovac's split pandemic influenza vaccine aims at protecting the pediatric and adolescent population. Based on the positive safety results of the Phase I trial, the Phase II study will be conducted to further collect the vaccine's safety data in children and adolescents, as well as assessing the immunogenicity of different doses.''

Sinovac received approval from the China State Food and Drug Administration (SFDA) in April 2007 to conduct clinical trials for two types of the H5N1 vaccine, namely Phase Ib and II trials of the H5N1 whole viron vaccine and Phase I and Phase II trials of the H5N1 split vaccine. In December 2007, Sinovac reported positive top-line results from the completed Phase II clinical trial of Panflu(TM), its pandemic influenza (H5N1) whole viron inactivated vaccine. In April 2008, Panflu(TM) was granted a production license by the China State Food and Drug Administration (SFDA). Panflu(TM) is the first and only approved vaccine available in China against the H5N1 influenza virus.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington / Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
2. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
3. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
4. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
5. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
6. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
7. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. Prolexys Pharmaceuticals Initiates Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... DUBLIN , Mar 22, 2017 Research ... Packaging Market Analysis & Trends - Industry Forecast to 2025" ... ... at a CAGR of around 7.1% over the next decade to ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... 22, 2017  Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced the latest line-up ... 2017 is a day full of presentations, posters, ... (QSP) community. The focus is to learn about ... accelerating drug research and development. The ...
(Date:3/22/2017)... Massachusetts , March 22, 2017 ... solutions, announced today that Newton-Wellesley Hospital, a nationally recognized medical ... significant improvement in patient outcomes following continued implementation of its ... overall reduction of 59% in median nurse response time to ... ...
Breaking Medicine Technology:
(Date:3/23/2017)... Segundo, CA (PRWEB) , ... March 23, 2017 ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. Verisys ... source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are delighted ...
(Date:3/23/2017)... Jersey (PRWEB) , ... March 23, 2017 , ... ... of herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams ... products. This competition was hosted jointly by HSN and Good Housekeeping. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored ... 2pm. All events will be located in the Main West Entrance of The ... Child ID event. No appointment is necessary and each child with a parent or ...
(Date:3/23/2017)... , ... March 23, 2017 , ... “Beyond and Back”: ... and Back” is the creation of published author Bonetta Rose, a wife, mother and ... lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... selected HealthiPASS, an innovative patient - centric payment system, to expand its focus ... improvements in the patient financial experience. , “At Ogden Clinic, we are ...
Breaking Medicine News(10 mins):